Immunotherapy with Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab with Cabozantinib for Patients with Advanced Kidney Cancer, The PDIGREE Study
Inclusion Criteria
- STEP I REGISTRATION CRITERIA
- Histologically documented renal cell carcinoma with clear cell component, including patients who have sarcomatoid features.
- Any metastatic disease, including visceral, lymph node, other soft tissue and bone, measurable per RECIST 1.1.
- Measurable disease as defined in the protocol.
- Must be intermediate or poor risk patient per International Metastatic Renal Cell Carcinoma Database (IMDC) criteria (1 or more of the following: Karnofsky performance status [KPS] < 80, < 1 year from diagnosis [including initial nephrectomy] to systemic treatment for metastatic disease, hemoglobin less than lower limit of normal [LLN], corrected calcium concentration greater than upper limit of normal [ULN], absolute neutrophil count greater than ULN, platelet count > ULN).
- Central nervous system (CNS) disease permitted, if stable and not otherwise causing symptoms or needing active treatment.
- Karnofsky performance status >= 70%.
- No prior treatment with PD-1, PD-L1, or CTLA-4 targeting agents (including but not limited to nivolumab, pembrolizumab, pidilizumab, durvalumab, atezolizumab, tremelimumab, and ipilimumab), or any other drug or antibody specifically targeting T-cell co-stimulation or checkpoint pathways. The only exception is for prior treatment with nivolumab or other PD-1/PD-L1/CTLA-4 targeting therapy on pre- or post-operative trials, as long as > 1 year since completion of systemic therapy.
- No prior previous systemic therapy for renal cell carcinoma (prior HD IL-2 [> 28 days] and prior adjuvant sunitinib > 180 days since completion and prior immunotherapy as above are allowed).
- No cancer therapy less than 28 days prior to registration; this includes radiation therapy, except for bone lesions less than 14 days prior to registration. There must be a complete recovery and no ongoing complications from radiotherapy.
- Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative serum or urine pregnancy test done =< 14 days prior to registration is required.
- Age >= 18 years
- Absolute neutrophil count (ANC) >= 1,500/mm^3.
- Platelet count >= 100,000/mm^3.
- Hemoglobin >= 8 g/dL.
- Calculated (Calc.) creatinine clearance >= 30 mL/min.
- Urine protein =< 1+ or urine protein to creatinine (UPC) ratio < 1.
- Total bilirubin =< 1.5 x upper limit of normal (ULN).
- Aspartate aminotransferase/alanine aminotransferase (AST/ALT) =< 2.5 x upper limit of normal (ULN) or < 5 x ULN if hepatic metastases present.
- STEP 2 REGISTRATION ELIGIBILITY CRITERIA
- Successful completion of at least 1 cycle of ipilimumab/nivolumab.
- Resolution of any treatment-related adverse events to grade 1 or less per dose modification section (this criteria does not include any adverse events [AEs] not attributable to treatment which are present due to disease). Exceptions for this criteria include patients receiving replacement hormone treatments (such as levothyroxine for treatment-related hypothyroidism or glucocorticoid replacement for adrenal insufficiency). Please contact study chair if further discussion is needed.
- No more than 70 days from last dose of ipilimumab/nivolumab.
Exclusion Criteria
- Active autoimmune disease requiring ongoing therapy.
- Ongoing acute toxicity > grade 2 from previous treatment.
- History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies.
- History of human immunodeficiency virus (HIV) or active hepatitis B/C, or active tuberculosis (purified protein derivative [PPD] response without active TB is allowed).
- Concurrent use of immunosuppressive medication including prednisone above 10 mg daily.
- Uncontrolled adrenal insufficiency.
- Uncontrolled hypertension (systolic blood pressure [BP] >150 mmHg or diastolic BP > 90 mmHg).
- Major surgery less than 28 days prior to registration.
- Any serious non-healing wound, ulcer, or bone fracture within 28 days prior to registration.
- Any arterial thrombotic events within 180 days prior to registration.
- Clinically significant hematuria, hematemesis, or hemoptysis within 12 weeks prior to registration.
- Cavitating pulmonary lesions or known endotracheal or endobronchial disease manifestations.
- Lesions encasing or invading any major blood vessels (this does not include tumor thrombus extending into/through renal vein/inferior vena cava [IVC]). Patients with tumor thrombus extending into/through renal vein are considered eligible.
- Moderate of severe hepatic impairment (Child-Pugh B or C).
- Any history of untreated pulmonary embolism or deep venous thrombosis (DVT) in the 180 days prior to registration. (Any asymptomatic, treated pulmonary embolism or asymptomatic, treated deep venous thrombosis > 30 days prior to registration allowed).
- Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms.
- Unstable cardiac arrhythmia within 6 months prior to registration.
- Any gastrointestinal (GI) bleeding =< 180 days, hemoptysis, or other signs of pulmonary hemorrhage =< 90 days prior to registration.
- History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, bowel obstruction, or gastric outlet obstruction within 180 days prior to registration.
- Active peptic ulcer disease, inflammatory bowel disease, or malabsorption syndrome within 28 days prior to registration.
- Untreated hypothyroidism, evidence of pancreatitis, history of organ transplant, or history of congenital QT syndrome.
- Active treatment with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct Xa inhibitor betrixaban or platelet inhibitors (e.g., clopidogrel) within 5 days of registration. Allowed anticoagulants include: prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH), therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, apixaban. Allowed also in patients with known brain metastases who are on a stable dose of the anticoagulant for at least 1 week prior to registration without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.
- Significant cardiac ischemia events (ST elevation myocardial infarction [STEMI] or non-ST elevation myocardial infarction [NSTEMI]) within 6 months or active NY Heart Association class 3-4 heart failure symptoms
Alaska
Anchorage
Fairbanks
Arizona
Kingman
Phoenix
Arkansas
Ft. Smith
Hot Springs
California
Anaheim
Arroyo Grande
Baldwin Park
Bellflower
Burbank
Clovis
Fontana
Harbor City
Irvine
La Jolla
Los Angeles
Ontario
Panorama City
Riverside
Sacramento
San Diego
San Francisco
San Luis Obispo
San Marcos
Santa Maria
Woodland Hills
Colorado
Aurora
Boulder
Centennial
Colorado Springs
Denver
Durango
Englewood
Fort Collins
Golden
Grand Junction
Greeley
Highlands Ranch
Lafayette
Lakewood
Littleton
Lone Tree
Longmont
Loveland
Parker
Pueblo
Thornton
Wheat Ridge
Connecticut
Stamford
Delaware
Frankford
Lewes
Newark
Rehoboth Beach
Seaford
Wilmington
District of Columbia
Washington
Florida
Fort Lauderdale
Gainesville
Orlando
Georgia
Atlanta
Duluth
Lawrenceville
Savannah
Snellville
Hawaii
Aiea
Honolulu
Lihue
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Fruitland
Meridian
Nampa
Post Falls
Sandpoint
Twin Falls
Illinois
Aurora
Bloomington
Burr Ridge
Canton
Carbondale
Carterville
Carthage
Centralia
Chicago
Danville
DeKalb
Decatur
Dixon
Effingham
Eureka
Galesburg
Geneva
Harvey
Joliet
Kewanee
Lake Forest
Macomb
Mattoon
Maywood
Melrose Park
Mount Vernon
New Lenox
O'Fallon
Orland Park
Ottawa
Pekin
Peoria
Peru
Princeton
Springfield
Swansea
Urbana
Warrenville
Yorkville
Indiana
Indianapolis
Mooresville
Richmond
Iowa
Ames
Boone
Clive
Council Bluffs
Creston
Des Moines
Fort Dodge
Jefferson
Marshalltown
Sioux City
West Des Moines
Kansas
Fairway
Garden City
Great Bend
Hays
Lawrence
Lenexa
Olathe
Overland Park
Pittsburg
Salina
Topeka
Westwood
Wichita
Kentucky
Bardstown
Corbin
Lexington
London
Louisville
Shepherdsville
Louisiana
Baton Rouge
Covington
Houma
Metairie
New Orleans
Maine
Augusta
Belfast
Biddeford
Brewer
Norway
Rockport
Sanford
South Portland
Maryland
Baltimore
Massachusetts
Boston
Springfield
Michigan
Adrian
Ann Arbor
Battle Creek
Brighton
Brownstown
Canton
Caro
Chelsea
Clarkston
Clinton Township
Dearborn
Detroit
East China
Escanaba
Flint
Grand Rapids
Grosse Pointe Woods
Jackson
Kalamazoo
Lansing
Livonia
Macomb Township
Marlette
Monroe
Muskegon
Niles
Norton Shores
Novi
Pontiac
Port Huron
Reed City
Rochester Hills
Saginaw
Saint Joseph
Shelby Township
Southfield
Sterling Heights
Tawas City
Traverse City
Warren
West Bloomfield
West Branch
Wyoming
Ypsilanti
Minnesota
Aitkin
Bemidji
Brainerd
Burnsville
Cambridge
Coon Rapids
Deer River
Detroit Lakes
Duluth
Edina
Fergus Falls
Fosston
Fridley
Hibbing
Maple Grove
Maplewood
Minneapolis
Monticello
New Ulm
Park Rapids
Princeton
Robbinsdale
Saint Cloud
Saint Louis Park
Saint Paul
Sandstone
Shakopee
Stillwater
Thief River Falls
Virginia
Waconia
Willmar
Woodbury
Worthington
Wyoming
Mississippi
Gulfport
Jackson
Missouri
Ballwin
Bolivar
Bonne Terre
Branson
Cape Girardeau
Columbia
Farmington
Independence
Jefferson City
Joplin
Kansas City
Rolla
Saint Joseph
Saint Louis
Sainte Genevieve
Springfield
Sullivan
Sunset Hills
Washington
Montana
Anaconda
Billings
Bozeman
Butte
Great Falls
Helena
Kalispell
Missoula
Nebraska
Grand Island
Kearney
Lincoln
Omaha
Papillion
Nevada
Carson City
Henderson
Las Vegas
Pahrump
Reno
New Hampshire
Concord
Manchester
New Jersey
Cape May Court House
Egg Harbor Township
Hackensack
Mullica Hill
New Brunswick
New Mexico
Albuquerque
New York
Auburn
Cooperstown
East Syracuse
Glens Falls
Lake Success
New York
Rochester
Stony Brook
Syracuse
North Carolina
Asheville
Chapel Hill
Clinton
Clyde
Durham
Goldsboro
Greenville
Hendersonville
Jacksonville
Kenansville
Kernersville
Kinston
Mount Airy
Richlands
Stateville
Thomasville
Wilkesboro
Winston-Salem
North Dakota
Bismarck
Fargo
Jamestown
Minot
Ohio
Beavercreek
Belpre
Boardman
Centerville
Chillicothe
Cincinnati
Columbus
Dayton
Delaware
Dublin
Findlay
Franklin
Gahanna
Greenville
Grove City
Kettering
Lancaster
Mansfield
Marietta
Marion
Mount Vernon
Newark
Perrysburg
Portsmouth
Springfield
Toledo
Troy
Warren
West Chester
Westerville
Youngstown
Zanesville
Oklahoma
Lawton
Oklahoma City
Tulsa
Oregon
Baker City
Bend
Clackamas
Coos Bay
Gresham
Newberg
Ontario
Portland
Redmond
Tualatin
Pennsylvania
Allentown
Bethlehem
Bryn Mawr
Chadds Ford
Collegeville
Danville
East Stroudsburg
Exton
Hazleton
Hershey
Lewisburg
Lewistown
Media
Newtown Square
Paoli
Pottsville
Sayre
Scranton
Selinsgrove
State College
Wilkes-Barre
Wynnewood
Puerto Rico
San Juan
South Carolina
Boiling Springs
Easley
Gaffney
Greenville
Greer
Seneca
Spartanburg
Union
South Dakota
Rapid City
Sioux Falls
Tennessee
Bristol
Cookeville
Kingsport
Texas
Austin
Bryan
Dallas
Fort Worth
Galveston
Richardson
Utah
American Fork
Cedar City
Logan
Murray
Ogden
Provo
Riverton
Saint George
Salt Lake City
Vermont
Berlin
Burlington
Virginia
Bristol
Fishersville
Lynchburg
Mechanicsville
Midlothian
Norfolk
Norton
Portsmouth
Richmond
South Hill
Suffolk
Washington
Aberdeen
Auburn
Bellevue
Bellingham
Bremerton
Burien
Centralia
Edmonds
Enumclaw
Everett
Federal Way
Gig Harbor
Issaquah
Kennewick
Lacey
Lakewood
Longview
Port Townsend
Poulsbo
Puyallup
Renton
Seattle
Sedro-Woolley
Shelton
Spokane
Spokane Valley
Tacoma
Vancouver
Walla Walla
Yelm
West Virginia
Bridgeport
Charleston
Huntington
Martinsburg
Morgantown
Parkersburg
Wisconsin
Antigo
Appleton
Ashland
Eau Claire
Green Bay
Madison
Manitowoc
Marinette
Marshfield
Medford
Menomonee Falls
Milwaukee
Minocqua
Mukwonago
New Richmond
Oconomowoc
Oconto Falls
Rice Lake
Sheboygan
Stevens Point
Sturgeon Bay
Waukesha
Wausau
West Bend
Weston
Wisconsin Rapids
Wyoming
Cheyenne
Cody
Sheridan
PRIMARY OBJECTIVE:
I. To compare the overall survival (OS) in patients with metastatic renal cell cancer (RCC) treated with ipilimumab-nivolumab followed by either nivolumab versus cabozantinib-nivolumab.
SECONDARY OBJECTIVES:
I. To determine progression free survival (PFS) of patients treated with nivolumab versus nivolumab-cabozantinib.
II. To evaluate the 12-month complete response rate in patients treated with ipilimumab-nivolumab followed by cabozantinib-nivolumab versus ipilimumab-nivolumab followed by nivolumab (patients who have complete response [CR] and relapse before 12 months will not be counted as a CR at 12-months).
III. To evaluate the rates of discontinuing therapy at 1 year.
IV. To compare objective response rates (ORR, assessed by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 and Immune Response Evaluation Criteria in Solid Tumors [iRECIST] criteria) for patients treated with ipilimumab-nivolumab followed by cabozantinib-nivolumab versus ipilimumab-nivolumab followed by nivolumab.
V. To document the adverse event profile of ipilimumab-nivolumab followed by cabozantinib-nivolumab.
BIOMARKER OBJECTIVES:
I. To evaluate biomarkers associated with exceptional responses in both arms (exceptional responses defined as CRs with treatment discontinuation at 12 months or 24 months).
II. To evaluate whether baseline IL-6 is predictive of outcome in patients treated with cabozantinib-containing regimen.
QUALITY OF LIFE (QOL) OBJECTIVES:
I. To compare health-related quality of life at 18 months post-registration as assessed by the Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index 19 (FKSI-19) between patients randomized to nivolumab (nivo) versus (vs) cabozantinib (cabo)/nivo.
II. To compare health-related quality of life as assessed by the FKSI-19 between patients randomized to nivo vs cabo/nivo at other time points.
III. To compare patient-reported fatigue using Patient-Reported Outcomes Measurement Information System (PROMIS)-Fatigue between patients randomized to nivo vs cabo/nivo.
IV. To compare quality-adjusted survival (overall survival x utility score assessed by EuroQol five-dimensional questionnaire [EQ5D-5L]) between patients randomized to nivo vs cabo/nivo.
OUTLINE:
INDUCTION: Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
TREATMENT:
Patients with unconfirmed but clinical progression of disease (iuPD) receive cabozantinib orally (PO) daily on days 1-28. Treatment repeats every 28 days until further disease progression or unacceptable toxicity.
Patients with unconfirmed CR (iCR) receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Patients with non-CR/non-PD or iuPD are randomized to 1 of 2 arms.
ARM A: Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 5 years.
Trial Phase Phase III
Trial Type Treatment
Lead Organization
Alliance for Clinical Trials in Oncology
Principal Investigator
Tian Zhang
- Primary ID A031704
- Secondary IDs NCI-2018-03694
- Clinicaltrials.gov ID NCT03793166